Belgian Vlitin SA - a VlitinRx Cmpany- Technlgical cmpany presentatin BIOWIN DAY 2014
Abut VlitinRx Wh we are Lab and Head ffice in Namur, Belgium Creatin: Oct 2010 8 emplyees + Internatinal Bard f Directrs What we d A life sciences cmpany fcused n develping bld-based diagnstic tests Beginning with diagnstic bld-based tests fr cancer The tests are based n the Cmpany s prprietary Nuclesmics platfrm
Nuclesmics verview The DNA in every cell is wund arund prteins cmplexes in a beads n a string structure. Each individual bead is called a nuclesme Nuclesme cnsist f DNA and histne prteins. Histnes and DNA are subjected t a variety f epigenetic mdificatins Cell death results in fragmentatin and release f nuclesmes int the bld In cancer, high cell turn ver results in large amunts f cell debris, verwhelming the recycling mechanism and leading t elevated bld nuclesme levels
NuQ Test Accessing the Epigenme Nuclesme HRP Reprter Capture Antibdy Prfiling antibdy NuQ assays identify and measure circulating nuclesme structures fr the presence f epigenetic signals within bld VlitinRx has develped five patentprtected families f NuQ duble antibdy ELISA assays: NuQ -X specific DNA mdificatins NuQ -V histne variants NuQ -M histne mdificatins NuQ -A nuclesme-prtein adducts NuQ -T ttal nuclesmes 20 different assays have been develped and can be used alne r in cmbinatin
Significant need fr Better CRC diagnstics Current CRC diagnstics: Clnscpy accurate but invasive and expensive; lw cmpliance FIT/FOBT fecal-based tests unpleasant; dn t pick up precancerus plyps; cmpliance prblems Bld ptimal fr early diagnsis: Fecal test cmpliance nly 50% Only bld test cmmnly used (PSA prstate cancer bld test) has high cmpliance (arund 85%) hwever test is nt very accurate (sensitivity 72%) 95% f peple wuld rather take a bld test than a clnscpy
NuQ Test Bld based CRC Diagnstic Published in Anticancer research: Clrectal cancer single-assay test (90 subjects) 75% detectin at 70% specificity Hldenrieder et. al. ANTICANCER RESEARCH 34: 2357-2362 (2014) 4 800-subject Danish CRC study design (symptmatic ppulatin) Initial representative 938-subject sample analysis NuQ CRC diagnstic test demnstrated: 84% sensitivity (accurate detectin) at 78% specificity 60% detectin f adenmas (plyps) Detectin f early (I r II) and late-stage (III r IV) disease with similar accuracy 3-assay test panel using abut 1 drp f bld serum in ttal Study grup were all aged ver 50; results were age- and gender-adjusted
NuQ Test Additinal Results t Date Presented at the internatinal Sciety f Onclgy and Bimarkers Cngress, March 2014 Finding in bth prstate (PCA) and clrectal cancer Pilt study: 39 subjects referred fr clnscpy, 9 male subject newly diagnsed with PCA and 10 male cntrl subjects Clrectal cancer: 86% detectin at 86% specificity 50% detectin f the precancerus plyps Prstate Cancer: 80% detectin at 70% specificity Prfiles f nuclesmes in tw cancers shwn t be different
Multiple clinical trials
NuQ Test Lung Cancer pilt study Sputum Lung cancer vs Healthy NuQ tests able t detect lung cancer in 85% f patients using airway secretin (sputum) and 76% using bld Findings are the first using NuQ platfrm utside bld. Samples were cllected at the Pneumlgy department f the CHU Liège 46 individuals with either NSCL cancer, chrnic bstructive pulmnary disease (COPD) r with n diseases Bld Lung cancer vs Healthy
Nuclesmics - Revlutinizing Cancer Diagnsis VlitnRx aims t meet the need fr cst effective, scalable and patient- and dctrfriendly test with its NuQ tests fr cancer diagnsis The tests are based n the Nuclesmics platfrm, which identifies and measures circulating nuclesme structures fr the presence f epigenetic cancer signals within the bld and nw airway secretin. Apply fr CE mark fr clrectal screening diagnsis in 2015 Select first CLIA partner fr initial US market entry in 2015 Nuclesmics bimarker platfrm is expandable t ther diseases (endmetrisis, inflammatry disease, thers) and the technlgy is adaptable t pint f care/pint f use.
VlitinRx Ptential partners We are lking fr partners t assist in: Extending ur diagnstics assays t ther cancer types and inflammatry diseases Develping new applicatins f the Nuclesmics platfrm Immunassays related innvative technlgies IVD manufacturers/subcntractrs Lgistic slutins
VlitinRx Revlutinizing Cancer Diagnsis Cntact Belgian Vlitin SA Rue du Séminaire, 20A BE-5000 Namur Belgium Web: vlitinrx.cm www.vlitinrx.cm Twitter, LinkedIn r Facebk Dr. Marielle Herzg Lead Scientist m.herzg@vlitinrx.cm Phne:+32 (0) 81 72 56 46 inf@vlitinrx.cm